Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of AGA111 for Lumbar Interbody Fusion in DDD
NCT05574543Phase 2Completed
- Sponsor
- Angitia Biopharmaceuticals
- Start
- Dec 2020
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AGA111 in degenerative disc disease (DDD) (3 arms), sponsored by Angitia Biopharmaceuticals. Primary endpoints: Number of participants with adverse events at 12 months and Number of participants who develop anti-drug antibody to AGA111 at 90 days. Started Dec 2020; status: completed.
02
Drugs
AGA111
03
Conditions
degenerative disc disease (DDD)
Beyond the preview
Go deeper on NCT05574543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05574543.